Phase 3 Readout~month

Phase 3 Topline: RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Ve

Indication
PDAC - Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma (PDAC); Resected Pancreatic Adenocarcinoma

Other upcoming events for RVMD

Phase 3 ReadoutPhase 3 Topline: RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus
Phase 3 ReadoutPhase 3 Topline: RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mon
Phase 3 ReadoutPhase 3 Topline: RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice o
Phase 3 ReadoutPhase 3 Topline: RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patie
Patent ExpiryPatent/Exclusivity Expiry: KHAPZORY

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Ve — RVMD Phase 3 Readout | BioSniper